In the News

This article covers a study conducted by the Population Council-Kenya in partnership with Tiny Totos and the Consortium of Women Empowerment finding that daycare centers help mothers reduce unpaid childcare responsibilities and quality childcare services contribute to better child development outcomes, including improved language skills, health, and nutrition.

This article covers Contraline's recent announcement of the close of a $92.5 million series B financing round to support the late-stage development of the Nestorone®/Testosterone transdermal gel. The NES/T gel was developed by the Population Council's Center for Biomedical Research and the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Contraline holds the global rights to develop and commercialize the program

Contraline announced the closing of a $92.5 million Series B financing to support the late-stage development of the Nestorone®/Testosterone transdermal gel for male contraception. The gel was developed by the Population Council's Center for Biomedical Research and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Contraline holds the exclusive worldwide rights to develop and commercialize the program.

Zeba Sathar, Pakistan Country Director, urges for data-driven and district-focused climate initiatives in this commentary published in DAWN.

This news segment highlights the impact of the Adolescent Girls Initiative-Kenya programme in Wajir County and the commitment by the local government to promote girls’ education.

At Breathe Pakistan, Zeba Sathar, Pakistan Country Director, spoke on a panel about the importance of accurate data in developing climate solutions.

The Women Deliver 2026 Conference in Melbourne opened with the launch of the Adolescent Girls’ Manifesto, placing adolescent voices at the center of discussions on gender equality, rights, and global accountability. The manifesto was released on April 27 as part of the Girls Deliver 2026 pre-conference, which brought together adolescent girls, policymakers, civil society groups, and global organizations ahead of the main gathering.

Duchesnay, a Canadian specialty pharmaceutical company with a long-standing commitment to women’s health, member of Duchesnay Pharmaceutical Group (DPG), announced the launch of Ringza in Canada. The Population Council developed the one year contraceptive vaginal ring (which received U.S. FDA approval in 2018 as Annovera®) and licensed it to Duchesnay for market access. Ringza/Annovera is the first and only contraceptive to provide an entire year of protection against unintended pregnancy while fully under a woman’s control.